Your session is about to expire
← Back to Search
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Part 1: Refractory Hormone Receptor Positive (HR+), Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Breast Cancer (BC)
Prior systemic Treatment: Part 1: HR-positive/HER2-negative BC
Timeline
Screening 3 weeks
Treatment Varies
Follow Up baseline up to approximately 24 months
Awards & highlights
CDK4i Trial Summary
This trial is testing a new drug, PF-07220060, to see if it is safe and effective when used alone or in combination with other drugs. The trial will be conducted in four parts, with escalating doses in the first part to determine the maximum tolerated dose (MTD) and recommended phase 2 dose (RP2D). The second part of the trial will test the drug in combination with two different endocrine therapies (letrozole and fulvestrant). The third part of the trial will assess the food effect of the RP2D dose from Part 1A. The fourth part of the trial will be an expansion for combination
Who is the study for?
This trial is for adults with advanced solid tumors, including specific breast and prostate cancers, who have not responded to existing therapies. Participants must have a certain level of physical fitness (ECOG PS 0 or 1) and adequate organ function. They should not have received cancer treatment within the last 2 weeks or be pregnant/breastfeeding.Check my eligibility
What is being tested?
The study tests PF-07220060's safety and effects both alone and with endocrine therapy in multiple doses. It includes patients with various cancers such as lung adenocarcinoma, colorectal cancer, liposarcoma, prostate cancer, and breast cancer.See study design
What are the potential side effects?
As this is an early-phase trial testing PF-07220060's safety, potential side effects are being studied but may include typical reactions like nausea, fatigue, allergic responses or more serious ones depending on individual patient factors.
CDK4i Trial Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowSelect...
My breast cancer is HR+ and HER2- and does not respond to hormone therapy.
Select...
My breast cancer is HR-positive and HER2-negative.
Select...
I have a measurable cancer lesion on my skin or bone.
Select...
My condition hasn't improved with current treatments.
Select...
I am fully active or restricted in physically strenuous activity but can do light work.
Select...
My cancer is NSCLC, prostate, CRC, liposarcoma, or has CDK4/CCND1 amplification.
Select...
My prostate cancer has spread and is not responding to hormone therapy.
CDK4i Trial Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ baseline up to approximately 24 months
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline up to approximately 24 months
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
DDI
Food Effect
Incidence of clinically significant AEs
+3 moreSecondary outcome measures
Apparent Oral Plasma Clearance (CL/F) in the Dose Escalation and Dose Finding portion
Area Under the Plasma Concentration Versus Time Curve Within One Dose Interval (AUCss,t) in the Dose Escalation and Dose Finding portion
Clinical Benefit Rate (CBR)
+22 moreCDK4i Trial Design
16Treatment groups
Experimental Treatment
Group I: 2D Combination Dose ExpansionExperimental Treatment2 Interventions
PF-07220060 with enzalutamide Combination Expansion
Group II: 2C Combination Dose ExpansionExperimental Treatment2 Interventions
PF-07220060 with fulvestrant Combination Expansion
Group III: 2B Combination Dose ExpansionExperimental Treatment2 Interventions
PF-07220060 with Letrozole Combination Expansion
Group IV: 2A Combination Dose ExpansionExperimental Treatment2 Interventions
PF-07220060 with fulvestrant combination dose expansion
Group V: 1F Combination Dose FindingExperimental Treatment2 Interventions
PF-07220060 with Enzalutamide Escalation
Group VI: 1E DDI CohortExperimental Treatment2 Interventions
PF-07220060 DDI with Midazolam
Group VII: 1D Monotherapy Food EffectExperimental Treatment1 Intervention
PF-07220060 Monotherapy Food Effect
Group VIII: 1C Combination Dose Finding Arm 2Experimental Treatment2 Interventions
PF-07220060 with Fulvestrant Combination Escalation
Group IX: 1C Combination Dose Finding Arm 1Experimental Treatment2 Interventions
PF-07220060 with Fulvestrant Combination Escalation
Group X: 1B Combination Dose Finding Arm 2Experimental Treatment2 Interventions
PF-07220060 with Letrozole Combination Escalation
Group XI: 1B Combination Dose Finding Arm 1Experimental Treatment2 Interventions
PF-07220060 with Letrozole combination Escalation
Group XII: 1A Monotherapy Escalation Arm 5Experimental Treatment1 Intervention
PF-07220060 Monotherapy Escalation
Group XIII: 1A Monotherapy Escalation Arm 4Experimental Treatment1 Intervention
PF-07220060 Monotherapy Escalation
Group XIV: 1A Monotherapy Escalation Arm 3Experimental Treatment1 Intervention
PF-07220060 Monotherapy Escalation
Group XV: 1A Monotherapy Escalation Arm 2Experimental Treatment1 Intervention
PF-07220060 Monotherapy Escalation
Group XVI: 1A Monotherapy Escalation Arm 1Experimental Treatment1 Intervention
PF-07220060 Monotherapy Escalation
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Enzalutamide
2014
Completed Phase 4
~2760
Midazolam
2018
Completed Phase 4
~1910
Fulvestrant
2011
Completed Phase 3
~3690
Letrozole
2002
Completed Phase 4
~2770
Research Highlights
Information in this section is not a recommendation. We encourage patients to speak with their healthcare team when evaluating any treatment decision.Mechanism Of Action
Side Effect Profile
Prior Approvals
Other Research
The most common treatments for Liposarcoma include chemotherapy, radiation therapy, and targeted therapies. Chemotherapy drugs like doxorubicin work by interfering with DNA replication, leading to cell death, which is crucial for targeting rapidly dividing cancer cells.
Radiation therapy uses high-energy rays to damage the DNA of cancer cells, preventing them from growing and dividing. Targeted therapies, such as pazopanib, inhibit specific proteins involved in tumor growth and angiogenesis.
Understanding these mechanisms is vital for Liposarcoma patients as it helps in selecting the most effective treatment based on the tumor's characteristics and potential response to therapy.
[Combined chemotherapy with 5-FU+cis-platin or UFT+cisplatin].How Taxol/paclitaxel kills cancer cells.Phase III trial of two investigational schedules of ifosfamide compared with standard-dose doxorubicin in advanced or metastatic soft tissue sarcoma: a European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Study.
[Combined chemotherapy with 5-FU+cis-platin or UFT+cisplatin].How Taxol/paclitaxel kills cancer cells.Phase III trial of two investigational schedules of ifosfamide compared with standard-dose doxorubicin in advanced or metastatic soft tissue sarcoma: a European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Study.
Find a Location
Who is running the clinical trial?
PfizerLead Sponsor
4,584 Previous Clinical Trials
14,634,002 Total Patients Enrolled
3 Trials studying Liposarcoma
138 Patients Enrolled for Liposarcoma
Pfizer CT.gov Call CenterStudy DirectorPfizer
3,488 Previous Clinical Trials
11,810,813 Total Patients Enrolled
1 Trials studying Liposarcoma
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:- I do not have active brain metastases or related conditions.I haven't had cancer treatment in the last 2 weeks.My breast cancer is HR+ and HER2- and does not respond to hormone therapy.My cancer returned while on or soon after aromatase inhibitor treatment. I've also had CDK4/6 inhibitor therapy.I haven't had any cancer except for certain skin cancers or localized cancer that hasn't spread in the last 3 years.My breast cancer is resistant to treatment and is both HR and HER2 positive.I have previously been treated with medications targeting cancer cell growth.My kidney, liver, and bone marrow are functioning well.My breast cancer is HR-positive and HER2-negative.I have a measurable cancer lesion on my skin or bone.My cancer can be measured by tests, and I may have cancer spread to bones but not just a rise in tumor markers.I have not had major surgery or radiation in the last 4 weeks.You have a visible and measurable tumor according to a specific set of rules called RECIST v1.1.I have prostate cancer.My condition hasn't improved with current treatments.I am fully active or restricted in physically strenuous activity but can do light work.I have an active stomach or bowel disease, or I've had surgery on my stomach.I cannot fast overnight or eat a high-fat, high-calorie meal due to surgery or dietary restrictions.My cancer is NSCLC, prostate, CRC, liposarcoma, or has CDK4/CCND1 amplification.My breast cancer is HR-positive and HER2-negative.My prostate cancer has spread and is not responding to hormone therapy.
Research Study Groups:
This trial has the following groups:- Group 1: 1C Combination Dose Finding Arm 2
- Group 2: 1A Monotherapy Escalation Arm 2
- Group 3: 1B Combination Dose Finding Arm 1
- Group 4: 2C Combination Dose Expansion
- Group 5: 1D Monotherapy Food Effect
- Group 6: 1F Combination Dose Finding
- Group 7: 1E DDI Cohort
- Group 8: 2D Combination Dose Expansion
- Group 9: 2A Combination Dose Expansion
- Group 10: 2B Combination Dose Expansion
- Group 11: 1A Monotherapy Escalation Arm 3
- Group 12: 1A Monotherapy Escalation Arm 4
- Group 13: 1B Combination Dose Finding Arm 2
- Group 14: 1A Monotherapy Escalation Arm 1
- Group 15: 1A Monotherapy Escalation Arm 5
- Group 16: 1C Combination Dose Finding Arm 1
Awards:
This trial has 1 awards, including:- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Share this study with friends
Copy Link
Messenger